Morgan Stanley analyst Terence Flynn maintained a Buy rating on AbbVie (ABBV – Research Report) today and set a price target of $239.00. The company’s shares closed last Friday at $186.96.

AbbVie. "This exciting milestone demonstrates our commitment to ongoing research and expanding indications in areas of high unmet need to help patients achieve better outcomes, including sustained ...

AbbVie has broken ground on a new $223 million expansion of its biologics manufacturing facility in Singapore, creating around 100 new jobs. The new investment will grow its workforce at the site ...

AbbVie has finally claimed FDA approval for its advanced Parkinson's disease therapy Vyalev, 18 months after the US regulator turned it down with a request for more data. Now, Vyalev (foscarbidopa ...

As of 10:28:41 AM EDT. Market Open.